Amit Goyal, MD

Amit Goyal, MD

Amit Goyal, MD

Amit Goyal (@AmitGoyalMD) is an interventional cardiology fellow at the Cleveland Clinic. He completed his medical school at the University of California, San Diego and went on to enjoy residency training in the Osler Program at Johns Hopkins, where he served as the Assistant Chief of Service of the Barker Firm. As ACS he founded Osler Grand Rounds, an interactive mystery case discussion, and helped establish a novel morning report structure integrating bedside skills education. He is looking forward to a career in interventional cardiology and medical education. He relishes time with friends and family including with his wife Riddhi and sons Dhruv, Aarav, and Atharv.

Articles by Amit Goyal, MD

Amit Goyal, MDInterventional Cardiology | June 13, 2025
OCTIVUS shows PCI outcomes improve with EAPCI-defined stent optimization, regardless of imaging modality.
Read More
Amit Goyal, MDInterventional Cardiology | June 11, 2025
LuX-Valve offers a safe, effective option for severe TR patients at high surgical risk.
Salman Allana, MDInterventional Cardiology | June 2, 2025
Dr. Salman Allana shares key insights on how operator volume impacts retrograde CTO PCI success and outcomes.
Amit Goyal, MDInterventional Cardiology | May 29, 2025
CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes.
Amit Goyal, MDCardioNerds | May 28, 2025
Delays in TAVI for acute decompensated aortic stenosis worsen outcomes.
Amit Goyal, MDCardioNerds | May 14, 2025
NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes
Amit Goyal, MDInterventional Cardiology | May 16, 2025
The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis.
Amit Goyal, MDCardiology | April 9, 2025
Dr. Amit Goyal of the CardioNerds analyzed the BHF PROTECT-TAVI trial.
Amit Goyal, MDCardioNerds | May 16, 2025
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
Amit Goyal, MDInterventional Cardiology | May 16, 2025
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Amit Goyal, MDCardiology | January 22, 2025
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.
Amit Goyal, MDCardioNerds | January 17, 2025
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
Amit Goyal, MDCardiology | January 14, 2025
The possibility of DCBs to rescue side branches during provisional coronary bifurcation stenting is appealing.
Amit Goyal, MDCardioNerds | January 3, 2025
Dr. Amit Goyal details the first-in-human study of the Magenta Elevate system.
Amit Goyal, MDAHA 2024: CardioNerds | November 26, 2024
A study highlights the significant HCRU and costs associated with ATTR-CM.
Amit Goyal, MDAHA 2024: CardioNerds | November 26, 2024
Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.
Amit Goyal, MDTCT 2024 | November 7, 2024
Results of the EARLY TAVR trial introduced a potential paradigm shift in managing asymptomatic high-gradient severe AS.
Amit Goyal, MDTCT 2024 | December 4, 2024
Two pivotal trials—EARLY TAVR and EVOLVED—were presented, each exploring early intervention in asymptomatic severe AS.
Amit Goyal, MDTCT 2024 | December 4, 2024
ECLIPSE investigated whether OA provides better outcomes than conventional balloon angioplasty in calcified coronary lesions.
Amit Goyal, MDTCT 2024 | December 4, 2024
An analysis of PROTECTED TAVR trial highlighted potential regional differences in the efficacy of CEP during TAVR.